GlassScriptPhysician profile
Amer Karam Karam
NPI 1851308860
$168,326.80
in general payments reported to CMS, 2019-2025
13 companies · $22K in 2025
The $22K reported for 2025 was more than what 94% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $23K · 2021: $29K · 2022: $29K · 2023: $12K · 2024: $7,069 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30K · Consulting Fee: $4,325 · Education: $4,065 · Food and Beverage: $1,315 · Travel and Lodging: $978.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,011.91 |
| Consulting Fee | $4,325.00 |
| Education | $4,064.50 |
| Food and Beverage | $1,315.49 |
| Travel and Lodging | $978.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $56,056.05 | 2020-2024 | Jemperli, Zejula |
| Clovis Oncology, INC. | $51,268.70 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $39,577.84 | 2019-2025 | Lynparza |
| Merck Sharp & Dohme LLC | $6,240.26 | 2019-2025 | Keytruda, Lynparza |
| Intuitive Surgical, INC. | $4,303.27 | 2019-2024 | Da Vinci Surgical System, Da Vinci Sp |
| Abbvie INC. | $3,807.48 | 2025 | |
| Corcept Therapeutics | $3,411.47 | 2025 | |
| Tesaro, INC. | $1,925.00 | 2019 | |
| Emd Serono Research & Development Institute, INC. | $1,425.00 | 2024 | |
| Conmed Corporation | $269.45 | 2022 | |
| Ethicon US, LLC | $27.65 | 2024 | Harmonic, N/A, Surgiflo Hemostatic Matrix |
| Pfizer INC. | $14.63 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amer Karam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.